High-risk neuroblastoma has remained a therapeutic challenge to pediatric oncologists. Longterm survival of high-risk patients is still below 40% despite intensive multimodal treatment, and new effective treatment regimens are thus urgently needed. Although the understanding of neuroblastoma pathogenesis has been substantially improved over the last years, few potential molecular targets for novel therapeutic strategies have been identified. In this study, we show that expression of the serine-threonine kinase PLK1 is strongly associated with highrisk features in neuroblastoma, and that the PLK1-specific inhibitor BI 2536 significantly Conclusions: Elevated PLK1 expression is significantly associated with high-risk neuroblastoma and unfavorable patient outcome. Inhibition of PLK1 using BI 2536 exhibits strong anti-tumor activity on human neuroblastoma cells in vitro and in vivo, opening encouraging new perspectives for the treatment of high-risk neuroblastoma.
Introduction
Neuroblastoma is the most common extracranial solid tumor in childhood and accounts for roughly 15% of pediatric oncology deaths (1) . The clinical courses of patients with neuroblastoma are highly variable, ranging from spontaneous regression to fatal progression of the disease. Spontaneous tumor involution is regularly observed in infants <18 months old with localized or stage 4S disease, which is defined by the age of the patient (<1 year) and dissemination limited to special sites. On the other hand, approximately half of the patients are currently classified to be at high-risk and these children have remained a therapeutic challenge for pediatric oncologists. Although neuroblastoma treatment has been significantly improved over the past decades, the overall survival for high-risk patients has remained less than 40% despite intensive multimodal therapy (1, 2) . Thus, novel effective treatment strategies are urgently needed to improve long-term outcome of current high-risk neuroblastoma patients.
A crucial step in tumorigenesis is the loss of cell cycle regulation control (3) (4) (5) . Protein phosphorylation by specific kinases is an important posttranscriptional process in the modulation of cell cycle kinetics and cell division (6, 7) . The serine/threonine-specific Pololike kinase 1 (PLK1) promotes cell cycle progression by regulating multiple steps during mitosis. PLK1 is a target of the DNA damage checkpoint and is essential for mitotic entry after recovery from DNA-damage induced arrest (8) . Elevated PLK1 expression has been found in numerous cancer entities and has been implicated to contribute to tumorigenesis. The oncogenic properties of PLK1 are believed to be due to its role in driving cell cycle progression (9) . Accordingly, NIH3T3 overexpressing PLK1 exhibit a transformed phenotype as demonstrated by the ability of these cells to grow in soft agar and to form tumors in nude mice (10) . On the other hand, studies comprising a variety of human cancer cell lines have
The effect of BI 2536 on the cell-cycle profile of neuroblastoma cells was assessed by flow cytometry. SK-N-AS and Kelly were exposed to various concentrations of BI 2536 (1 nmol/L, 5 nmol/L, 25 nmol/L and 125 nmol/L) for 14h and 72h and the cell cycle profiles were determined by flow cytometry as described previously (20) . Briefly, the cells were harvested with versene, treated with a citric acid buffer (2.1% citric acid and 0.5% Tween 20 in dH 2 O) and stained using a phosphate buffer (pH 8.0, 7.2 g Na 2 HPO 4 x 2H 2 O in 100 ml Figure 1a ). PLK1 transcript levels were elevated in patients older than 18 months at diagnosis (p<0.001; Figure 1b ) as well as in tumors with MYCN amplification (p<0.001; Figure 1c ). Furthermore, high PLK1 expression was significantly associated with unfavorable gene expression-based classification (p<0.001; Figure 1d ) according to a highly accurate classifier that we have previously defined using the prediction analysis for microarrays algorithm (PAM) (21, 22) . This predictive signature comprises 144 genes, but does not include PLK1, suggesting that elevated PLK1 mRNA levels are associated with an aggressive molecular neuroblastoma phenotype.
In addition, we determined the association of PLK1 expression levels with patient outcome. For this purpose, patients were divided into four quartiles (n=119 each) according to the PLK1 expression levels, and Kaplan-Meier estimates were compared by log-rank test.
Consistent with the correlation of high PLK1 transcript levels with unfavorable prognostic markers, it turned out that PLK1 expression was gradually associated with poor event-free and overall survival (Figures 1e and 1f ). Together, the strong association of elevated PLK1 transcript levels with unfavorable prognostic markers and poor outcome of neuroblastoma patients suggest that PLK1 could be utilized as a molecular target in high-risk neuroblastoma treatment. 
Discussion
Treatment of high-risk neuroblastoma patients has remained a challenge for pediatric oncologists. Current therapeutic strategies comprise dose-intensive induction chemotherapy, surgery, radiotherapy as well as myeloablative therapy followed by autologous stem cell rescue. In addition, immunotherapy using monoclonal antibodies and differentiation therapy using retinoic acid has been shown to contribute to maintenance of remission (27) .
Nevertheless, long-term outcome of these children has remained less than 40% (1, 2). In addition, toxicity from current therapy regimens is already significant, giving little room to further intensify conventional chemotherapy. Thus, alternative treatment strategies are urgently needed in order to improve survival and cure rates of these patients.
Targeting key components of the mitotic machinery like the Polo-like kinase 1 (PLK1)
represents a promising strategy in cancer therapy in general (11, 12, 14) . Elevated PLK1 levels have been found in many cancer entities as compared to their normal counterparts including breast, colorectal and non-small-cell lung cancer, melanoma, and hepatoblastoma (9, 28) . Moreover, PLK1 expression levels have been observed to correlate with the metastatic potential of tumors (29) and with the prognosis of cancer patients (28, (30) (31) (32) . Depletion or specific inhibition of PLK1 results in reduced survival of various types of cancer cells in vitro and inhibition of tumor growth in vivo in xenograft models (15, 33, 34) . PLK1 inhibition specifically induces spindle assembly checkpoint-induced prometaphase arrest (13) , which may avoid some of the severe side effects commonly observed with other anti-mitotic agents such as taxanes and Vinca alkaloid derivatives that affect many critical cellular processes (e.g., axonal transport) unrelated to mitosis (14, 35) . Currently, several PLK inhibitors from various drug classes are explored in a number of early clinical trials (17) .
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